Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25390723 | 0.90 | STS (0.53) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL519045 | 0.90 | STS (0.53) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL4167179 | 0.89 | STS (0.51) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL15507263 | 0.89 | STS (0.51) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL13602129 | 0.85 | KEAP1 (0.48) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL28331171 | 0.85 | KEAP1 (0.48) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL23051556 | 0.85 | STS (0.48) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL20794687 | 0.81 | KMT2A (0.48) | STSGPR119TP53TDP1SMN1; SMN2 | |
| SCHEMBL616004 | 0.79 | STS (0.60) | KEAP1NFE2L2STSGPR119KDM4E | |
| SCHEMBL12491982 | 0.79 | STS (0.49) | KEAP1NFE2L2STSGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK6 | KEAP1 905/4885NFE2L2 1364/4885STS 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.